Related Experiment Video
Updated: Nov 18, 2025
09:57
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
2.2K
Interleukin-6 Function and Targeting in Prostate Cancer.
1Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. zoran.culig@i-med.ac.at.
Advances in Experimental Medicine and Biology
|February 9, 2021
Summary
Interleukin-6 (IL-6) is a key cytokine in prostate cancer, promoting tumor growth and metastasis. While anti-IL-6 therapies show promise, clinical trials need optimized strategies for patient survival.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Interleukin-6 (IL-6) is a proinflammatory cytokine implicated in various cancer pathologies.
- IL-6 expression and function are extensively studied in prostate cancer (PC) cellular models and clinical samples.
- High IL-6 levels are found in androgen-unresponsive PC cells, and STAT3 phosphorylation is a hallmark of PC.
Purpose of the Study:
- To review the role of IL-6 in prostate cancer pathogenesis.
- To evaluate the efficacy of targeting IL-6 in prostate cancer.
- To discuss future clinical trial designs for anti-IL-6 therapies.
Main Methods:
- Literature review of studies on IL-6 in prostate cancer.
- Analysis of experimental and clinical data on IL-6 targeting strategies.
- Examination of the impact of IL-6 on prostate cancer cell proliferation, migration, and invasion.
Main Results:
- IL-6 promotes prostate cancer proliferation, migration, and invasion.
- Anti-IL-6 antibodies inhibit prostate cancer growth in vitro and in vivo.
- Clinical application of anti-IL-6 therapies has not yet improved survival in metastatic prostate cancer patients.
Conclusions:
- IL-6 plays a significant role in prostate cancer progression.
- Targeting IL-6 presents a potential therapeutic strategy, but clinical outcomes require further investigation.
- Future clinical trials should explore novel treatment schedules and combinations for anti-IL-6 therapies.
Related Concept Videos
01:24T Cell Types and Functions
1.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K
02:17The Tumor Microenvironment
7.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.3K
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
01:27Tumor Immunotherapy
861
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
861